Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

Cutting Through Cost Barriers for Heart Failure Medications

03/02/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the latest installment of Talking Therapeutics, Dr Jennings provides a brief history of heart failure medications and discusses the cost effectiveness of quadruple, triple, and double therapy regimens.

In the latest installment of...

03/02/2023

Pharmacy Learning Network

Talking Therapeutics

Less Is Certainly More: The Frontier of Weight Loss Pharmacotherapy

07/14/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s issue of Talking Therapeutics, Dr Jennings explores the latest data surrounding a promising new agent for weight loss.

In this week’s issue of Talking...

07/14/2021

Pharmacy Learning Network

Talking Therapeutics

Pause on Surgery for Prosthetic Valve Thrombosis

03/10/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the newest installment of Talking Therapeutics, Dr Jennings reviews new data comparing surgery to thrombolytic therapy for prosthetic valve thrombosis and predicts where the future of care may be headed.

In the newest installment of...

03/10/2022

Pharmacy Learning Network

Talking Therapeutics

A New Booster to Fight COVID-19

10/13/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's Talking Therapeutics, Dr Jennings highlights research comparing the effectiveness of the new and old COVID-19 boosters.

In this week's Talking...

10/13/2022

Pharmacy Learning Network

Talking Therapeutics

Another Win for GLP-1 Agonists

11/08/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews the latest new on the potential for the GLP-1 agonists to slow the progression of CKD in patients with diabetes.

Dr Jennings reviews the latest...

11/08/2023

Pharmacy Learning Network

Talking Therapeutics

Targeted COVID-19 Therapies in Immunosuppressed Patients

08/18/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the latest installment of Talking Therapeutics, Dr Jennings shares data on the efficacy of several COVID-19 treatments in solid-organ transplant recipients.

In the latest installment of...

08/18/2022

Pharmacy Learning Network

Talking Therapeutics

I Want More, More, More…Blood Pressure and Cholesterol Lowering

10/06/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

This week, Dr Jennings reviews two recently published papers that shed light on the optimal amount of “more” for patients in search of reducing residual cardiovascular risk.

This week, Dr Jennings reviews...

10/06/2021

Pharmacy Learning Network

Talking Therapeutics

Getting Hyped for a New Hypertrophic Obstructive Cardiomyopathy Drug Therapy

05/12/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the latest installment of Talking Therapeutics, Dr Jennings explores safety considerations of mavacamten for treating patients with hypertrophic obstructive cardiomyopathy.

In the latest installment of...

05/12/2022

Pharmacy Learning Network

Talking Therapeutics

ACC.23 Updates: New Data on Cholesterol-Lowering Therapies

03/09/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings highlights research from the American College of Cardiology 2023 Annual Meeting, focusing on strategies for using statins and bempedoic acid to reduce low-density lipoprotein cholesterol.

Dr Jennings highlights research...

03/09/2023

Pharmacy Learning Network

Talking Therapeutics

Quad Therapy for Chronic Kidney Disease is on the Horizon

02/09/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s installment of Talking Therapeutics, Dr Jennings reviews a new study addressing risk reduction in chronic kidney disease with the use of quad therapy.

In this week’s installment of...

02/09/2024

Pharmacy Learning Network